Together with GSK, the Boston-based research team will focus on understanding how dysfunctional lung epithelial cells initiate and perpetuate the disease, including alveolar type 2 (AT2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback